{{Rsnum
|rsid=11045585
|Gene=SLCO1B3
|Chromosome=12
|position=20892760
|Orientation=plus
|GMAF=0.1662
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=SLCO1B3
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 72.3 | 25.9 | 1.8
| HCB | 64.2 | 34.3 | 1.5
| JPT | 73.5 | 22.1 | 4.4
| YRI | 61.9 | 35.4 | 2.7
| ASW | 70.2 | 24.6 | 5.3
| CHB | 64.2 | 34.3 | 1.5
| CHD | 71.6 | 27.5 | 0.9
| GIH | 91.1 | 8.9 | 0.0
| LWK | 56.4 | 37.3 | 6.4
| MEX | 79.3 | 20.7 | 0.0
| MKK | 62.8 | 35.3 | 1.9
| TSI | 79.4 | 20.6 | 0.0
| HapMapRevision=28
}}
{{PMID|18294295}} [[rs12762549]] and [[rs11045585]] can be used to predict whether [[docetaxel]] will induce leukopenia/neutropenia, according to a study of ~100 Japanese patients. When patients were classified into three groups by the scoring system based on the genotypes of these two SNPs, patients with a score of 1 or 2 were shown to have a significantly higher risk of docetaxel-induced leukopenia/neutropenia as compared to those with a score of 0 (P = 0.0000057; odds ratio [OR], 7.00; 95% CI [confidence interval], 2.95-16.59). This prediction system correctly classified 69.2% of severe leukopenia/neutropenia and 75.7% of non-leukopenia/neutropenia into the respective categories.

[Effect percentages provided in table are raw population fractions taken from the referenced study based on rs11045585 only.  Total population size = 113.  Breakdown: leukopenia/neutropenia: AA=20 AG=19; non-leukopenia/neutropenia: AA=63 AG=11]

{{PharmGKB
|RSID=rs11045585
|Name_s=
|Gene_s=SLCO1B3
|Feature=
|Evidence=PubMed ID:18294295
|Annotation=A case-control association study in 84 patients who received docetaxel chemotherapy found a significant association of rs11045585 in SLCO1B3 with docetaxel-induced leukopenia/neutropenia.
|Drugs=docetaxel
|Drug Classes=
|Diseases=Leukopenia; Neutropenia
|Curation Level=Curated
|PharmGKB Accession ID=PA162191295
}}

{{PMID Auto
|PMID=21691256
|Title=Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose
}}

{{PMID Auto
|PMID=21468756
|Title=The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
}}

{{PMID Auto
|PMID=21673613
|Title=The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers.
}}

{{PMID Auto
|PMID=21829131
|Title=The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers.
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs11045585
|overall_frequency_n=19
|overall_frequency_d=128
|overall_frequency=0.148438
|n_genomes=14
|n_genomes_annotated=0
|n_haplomes=15
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}